evipedia.ai
← Back

Pycnogenol for Health & Longevity

Evidence Review created on 10/30/2026 using AI4L / Opus 5.5

Also known as: French Maritime Pine Bark Extract, Maritime Pine Bark Extract, Pine Bark Extract, Maritime Pine Extract, Pinus pinaster Bark Extract

Motivation

Pycnogenol is a standardized extract of the bark of the French maritime pine, a tree grown along the Atlantic coast of southwestern France. It is a concentrated source of plant pigments related to those in tea, cocoa and grapes. It draws interest because these compounds are thought to act on the inner lining of blood vessels, on inflammation and on blood clotting, processes that shape how circulation and joints age.

The extract has been sold for decades and is one of the most heavily studied branded plant supplements, with well over a hundred human trials, many on circulation, joint discomfort and blood sugar. Much of that research was paid for by the company that owns the brand name, which led independent reviewers and, more recently, university-led trials to examine the same questions with fewer ties to the maker.

This review examines what controlled human evidence shows about the benefits and risks of Pycnogenol for health-focused adults, how the maker’s role shapes that evidence, and which doses, interactions, sourcing standards and monitoring steps trials and practitioners describe.

Benefits - Risks - Protocol - Conclusion

These items give high-level overviews of Pycnogenol from a supplement magazine, a skeptic and academic reviewers.

No relevant content was found from Peter Attia, Andrew Huberman or Lifespan.io in web or on-site searches. Rhonda Patrick’s only match is a members-only question-and-answer session (FoundMyFitness Q&A #14), which is behind a paywall. Only four items are listed: Chris Kresser’s two matches, podcasts on aspirin alternatives (Kresser RHR podcast) and on histamine intolerance (reactions caused by impaired histamine breakdown) (Kresser histamine podcast), mention Pycnogenol only in passing, too briefly to serve as an overview.

Grokipedia

Pycnogenol

AI-written encyclopedia entry covering origin, standardization, research volume and claimed uses; its framing closely follows manufacturer materials, so it summarizes claims rather than appraising the evidence.

Examine

Pycnogenol

Independent evidence summary rating the support for venous insufficiency and osteoarthritis symptoms as relatively weak, with outcome-by-outcome grading of the human trials.

ConsumerLab

What is Pycnogenol, does it work, and is it the same as other pine bark extracts?

Question-and-answer article summarizing the clinical evidence by condition and noting that many studies were small and maker-funded; ConsumerLab has not published a laboratory test of Pycnogenol products.

Systematic Reviews

These systematic reviews and meta-analyses cover the effects of Pycnogenol and related pine bark extracts on chronic disorders and cardiometabolic risk factors.

The principal risk is represented only by the Cochrane review; no systematic review or meta-analysis has examined adverse events of Pycnogenol as its main question.

Mechanism of Action

Pycnogenol is a water extract standardized to 65–75% procyanidins (chains of catechin and epicatechin units, as in cocoa and tea), plus the single units catechin and taxifolin and several phenolic acids (a review, Bayer 2024).

  • Absorption and metabolism: Small constituents are absorbed from the small intestine; procyanidin chains reach the colon, where gut bacteria convert them to the metabolite M1 (a valerolactone breakdown product of catechin), which enters blood cells, joint fluid and saliva (same review, Bayer 2024).
  • Pharmacokinetics: After a single 300 mg dose, constituents remained detectable across the 14-hour sampling period, with extensive phase II conjugation (attachment of sulfate or glucuronic acid for excretion) varying widely between people (Grimm 2006). Elimination is mainly through the kidneys; no human data on cytochrome P450 enzymes (the liver’s main drug-processing enzymes) exist.
  • Blood vessel lining: Pycnogenol increased endothelium-dependent vasodilation (widening driven by the inner vessel lining), an effect abolished by blocking nitric oxide (NO, the gas that relaxes blood vessels) synthesis (Nishioka 2007).
  • Inflammation: Plasma from volunteers after intake inhibited NF-κB (a master switch for inflammatory genes) and MMP-9 (matrix metalloproteinase 9, a tissue-degrading enzyme) (Grimm 2006) and COX-1 and COX-2 (cyclooxygenase enzymes, the targets of aspirin and ibuprofen) (Schäfer 2006).
  • Platelets: It reduced smoking-induced platelet aggregation (clumping of clotting cells) (Pütter 1999).
  • Competing view: The original “antioxidant” explanation is weakly supported: in healthy adults, 200 mg/day did not raise blood antioxidant capacity or vitamin C (Silliman 2003), so vascular and anti-inflammatory effects are now favored.

Historical Context & Evolution

In a retold folk account, a French explorer in 1535 treated scurvy in his icebound crew with pine-bark tea, and the bark was later used for inflammation and anemia (Drugs.com monograph).

  • Origin as a branded extract: The standardized extract is a proprietary product of Horphag Research in Geneva (a review, Weichmann 2024) and conforms to the United States Pharmacopeia monograph “Maritime Pine Extract” (a review, Bayer 2024). Confusion arose when grape seed extract was marketed as “pycnogenol” (Drugs.com monograph).
  • From antioxidant to vascular claims: Interest in health optimization began with its antioxidant positioning. Healthy-adult antioxidant results were mixed: a small uncontrolled study found a rise (Devaraj 2002), a non-randomized one none (Silliman 2003); research shifted to blood-vessel function, venous symptoms, joints and blood sugar.
  • Who produced the evidence: Most trials were funded by the manufacturer, and a large share came from one Italian group (Belcaro and Cesarone). The Cochrane reviews of 2012 and 2020 judged the evidence too weak for firm conclusions, citing small samples and poor reporting rather than disproof (Schoonees 2012, Robertson 2020).
  • What changed recently: Trials led by groups without the maker’s co-authors added results on both sides: a Stanford trial of a different pine bark extract found no cardiovascular benefit (Drieling 2010), while a Zurich cardiology trial found improved vessel function (Enseleit 2012).
  • Structural incentives: Insurers and national health systems do not reimburse it, so funding has come mainly from the maker, whose incentive favors positive findings.

Expected Benefits

Most trials below were funded by Horphag Research, the manufacturer and trademark holder, and many list its long-standing adviser Peter Rohdewald as co-author; this conflict of interest applies throughout unless an item states otherwise.

High 🟩 🟩 🟩

Chronic venous insufficiency symptoms

In chronic venous insufficiency (CVI, poor blood return through leg veins causing swelling, heaviness and pain), placebo-controlled trials from two independent Italian groups, Arcangeli (Florence) and Petrassi (L’Aquila), found less leg edema (fluid swelling in tissue), heaviness and pain after two months at 300 mg/day (Arcangeli 2000, Petrassi 2000). The Belcaro/Cesarone group reported larger improvement than with diosmin-hesperidin (an established vein medication) (Cesarone 2006). The trials are small, and Cochrane rates the certainty very low.

Magnitude: Pain score 0.59 points lower than placebo (95% CI, the confidence interval within which the true effect likely lies: −1.02 to −0.16) in one trial of 40 participants, as analyzed by Robertson 2020.

Diabetic and vascular retinopathy

In retinopathy (damage to the small blood vessels of the retina, mostly from diabetes), placebo-controlled trials from two groups, Spadea (L’Aquila, 40 patients, 150 mg/day) and the Belcaro group (Steigerwalt, 46 patients with early diabetic retinopathy), found stable or improved visual acuity and less retinal swelling and leakage with Pycnogenol, while placebo groups worsened or stayed unchanged (Spadea 2001, Steigerwalt 2009). Both trials are small and short; half of Spadea’s patients were treated open-label, and the second trial includes a manufacturer employee as co-author.

Magnitude: Visual acuity on the Snellen chart improved from 14/20 to 17/20 after 2 months with Pycnogenol, while the placebo group showed no change; not compared between groups (Steigerwalt 2009).

Menopausal symptoms

Two independent randomized controlled trials (RCTs, studies that assign treatment by chance) in perimenopausal women reported symptom relief: Yang (Taiwan, 155 completers, 200 mg/day) on the Women’s Health Questionnaire (Yang 2007), and Kohama (Japan, 170 women, 60 mg/day for 3 months), especially for vasomotor symptoms (hot flashes) and sleep problems despite a sizeable placebo response (Kohama 2013). Yang’s trial includes the manufacturer’s adviser as co-author. Neither trial measured long-term outcomes.

Magnitude: The Kupperman index (a validated menopausal symptom severity score) fell 56% with Pycnogenol versus 39% with placebo at 12 weeks, a significant between-group difference; no confidence interval was reported (Kohama 2013).

Asthma control

Placebo-controlled trials from two independent groups found benefit. In a crossover trial (each participant receives both treatments in turn) of 26 adults (22 completers), the University of Arizona group (Hosseini) saw most respond to Pycnogenol rather than placebo, with lower blood leukotrienes (inflammatory signaling molecules that narrow airways) (Hosseini 2001). In 60 children, a Loma Linda University group (Lau) found better lung function and less rescue-inhaler use (Lau 2004). Both trials are small and short, and Cochrane rates them very low certainty.

Magnitude: FEV1 (forced expiratory volume in one second, the air exhaled in the first second) 7.0 percentage points of predicted higher than placebo (95% CI 0.10 to 13.90) in one adult trial of 44 participants, as analyzed by Robertson 2020.

Medium 🟩 🟩

Knee osteoarthritis pain and function

Placebo-controlled trials in mild-to-moderate knee osteoarthritis from Bratislava (Cisár, 100 patients) and Chieti (Belcaro, 156), plus a 37-patient trial analyzed in the Cochrane review (Robertson 2020), reported better WOMAC scores (Western Ontario and McMaster Universities Osteoarthritis Index, a validated pain, stiffness and function scale) and less use of pain medication over 3 months at 100–150 mg/day (Cisár 2008, Belcaro 2008). All three are manufacturer-linked, so they are not independent replications. A supplement meta-analysis rated the short-term pain effect large but very low quality (Liu 2018).

Magnitude: Composite WOMAC score 730 points lower than placebo (95% CI −1012 to −448) in one trial of 37 participants, as analyzed by Robertson 2020; in the Belcaro trial, the global WOMAC score fell 56% versus 9.6% with placebo, not compared between groups (Belcaro 2008).

Glycemic control in type 2 diabetes ⚠️ Conflicted

Added to standard diabetes treatment, 100–125 mg/day lowered fasting glucose more than placebo in trials from Beijing and Arizona (Liu 2004, Zibadi 2008); HbA1c (glycated hemoglobin, a 3-month glucose average) differed from placebo only in the first month in Beijing. Both list the manufacturer’s adviser as co-author. A 24-trial meta-analysis pooled the effect (Malekahmadi 2019); the Cochrane review reports a mixed type 1 and 2 trial without HbA1c difference (Robertson 2020). Net reading: a modest add-on glucose reduction in type 2 diabetes is supported, but by small manufacturer-linked trials.

Magnitude: HbA1c 0.29 percentage points lower than control (95% CI −0.56 to −0.01) and fasting glucose 5.86 mg/dL lower (95% CI −9.56 to −2.15) (Malekahmadi 2019).

Blood lipids ⚠️ Conflicted

LDL (low-density lipoprotein) cholesterol fell within the Pycnogenol groups of placebo-controlled trials from Arizona (Zibadi, type 2 diabetes) and Bratislava (Trebaticky, men with diabetes), but neither abstract reports a between-group test (Zibadi 2008, Trebaticky 2019). A meta-analysis of 24 trials found lower LDL and higher HDL (high-density lipoprotein) cholesterol (Malekahmadi 2019); smaller ones of 14 and 7 trials found LDL unchanged (Hadi 2019, Sahebkar 2014). Net reading: the largest pooled analysis supports a small LDL reduction, but two others do not.

Magnitude: LDL 7.12 mg/dL lower than control (95% CI −13.66 to −0.58) and HDL 3.27 mg/dL higher (95% CI 0.87 to 5.66) (Malekahmadi 2019); in Hadi 2019, LDL 3.61 mg/dL lower (95% CI −8.76 to 1.55, not significant) and HDL 3.27 mg/dL higher (95% CI 0.19 to 6.36).

Erectile function

In a blinded placebo-controlled trial of 53 men with erectile dysfunction from a Bratislava group without the manufacturer’s adviser, Pycnogenol alone improved IIEF-5 scores (International Index of Erectile Function, a validated 5-item questionnaire), more so in men with diabetes (Trebaticky 2019). Most other trials, pooled in a meta-analysis (Tian 2023), combine it with L-arginine (an amino acid that feeds nitric oxide production), so their effect cannot be assigned to Pycnogenol alone.

Magnitude: IIEF-5 scores rose 45% (men with diabetes) and 22% (men without diabetes) with Pycnogenol, while placebo showed no change; not compared between groups (Trebaticky 2019).

Cognitive performance in older adults

In 101 healthy adults aged 60–85 in Melbourne, 150 mg/day for 3 months improved working memory (holding and using information over seconds) and lowered F2-isoprostanes (markers of fat oxidation) relative to placebo, without changes in concentration or psychomotor speed (Ryan 2008). A network meta-analysis (a method comparing many treatments at once) ranked Pycnogenol highest among botanicals for mild cognitive impairment (Yang 2025). The Melbourne group discloses manufacturer funding.

Magnitude: Working memory improved over 3 months relative to placebo in adults aged 60–85, with no change in other cognitive domains; the trial abstract and the reviews citing it report no outcome figure (Ryan 2008).

In 198 moderate-to-high-risk travelers on flights of about 8 hours, the Belcaro group found no clots with Pycnogenol (200 mg before the flight, 200 mg 6 hours later, 100 mg the next day) versus five thromboses in the placebo group, detected by ultrasound (Belcaro 2004). Only one group has studied this, and the comparator was placebo, not standard compression or anticoagulation (medication that slows blood clotting).

Magnitude: Thrombotic events in 0% of the Pycnogenol group versus 5.15% (5 events, one deep and four superficial vein thromboses) of the placebo group among completers (Belcaro 2004).

Attention symptoms in attention-deficit hyperactivity disorder ⚠️ Conflicted ⭕️ Not Central to Health & Longevity

In 61 children with ADHD (attention-deficit hyperactivity disorder), 1 mg/kg/day for 4 weeks reduced hyperactivity and improved attention versus placebo, with relapse after stopping (Trebatická 2006). In a smaller crossover trial of 24 adults, neither Pycnogenol nor methylphenidate (a stimulant ADHD medication) beat placebo (Tenenbaum 2002). This bears on a childhood psychiatric condition rather than on aging. Net reading: a pediatric signal exists, while the only adult trial was null.

Magnitude: Visual-motoric coordination and concentration score 3.37 points higher than placebo (95% CI 2.41 to 4.33) in 57 children, as analyzed by Robertson 2020.

Melasma ⭕️ Not Central to Health & Longevity

In an independent Brazilian trial of 44 women with facial melasma (patchy brown facial pigmentation), 75 mg twice daily added to sunscreen and a bleaching cream reduced pigmentation more than placebo (Lima 2021). A systematic review of natural melasma treatments counts it among effective agents (Morais 2026). This bears on skin appearance, not on disease risk or lifespan.

Magnitude: mMASI (modified Melasma Area and Severity Index) fell 49% (95% CI 36% to 61%) with Pycnogenol versus 34% (95% CI 16% to 47%) with placebo; the between-group difference was significant (Lima 2021).

Low 🟩

Blood pressure ⚠️ Conflicted

A meta-analysis of 24 trials found small reductions (Malekahmadi 2019). Restricted to seven double-blind trials, no significant effect was found (Fogacci 2020), and a Zurich trial found no 24-hour blood pressure change (Enseleit 2012). Net reading: any effect is small and absent in the best-blinded trials.

Magnitude: Systolic 2.54 mm Hg lower (95% CI −4.08 to −0.99) and diastolic 1.76 mm Hg lower (95% CI −3.12 to −0.41) than control across all trials (Malekahmadi 2019); no significant difference in double-blind trials (Fogacci 2020).

Body weight ⚠️ Conflicted

Pycnogenol-only pooling found a small BMI (body mass index, weight relative to height) reduction (Malekahmadi 2019); pooling all pine bark extracts found lower weight but no BMI or waist change (Mohammadi 2025). Weight was rarely a primary outcome. Net reading: any weight effect is small and inconsistent.

Magnitude: BMI 0.47 kg/m² lower (95% CI −0.90 to −0.03) than control (Malekahmadi 2019); body weight 1.37 kg lower (95% CI −1.86 to −0.88) across all pine bark extracts (Mohammadi 2025).

Post-COVID-19 symptoms ⚠️ Conflicted

An open Belcaro study of 60 people reported better recovery than standard care (Belcaro 2022). The larger quadruple-blind Zurich PYCNOVID trial (153 adults, 200 mg/day) found no difference, per its secondary analysis (Kopp 2026; design in Radtke 2024). Net reading: the stronger trial shows no benefit.

Magnitude: EQ-VAS (EuroQol visual analogue scale, 0–100 self-rated health) change 0.54 points higher than placebo (95% CI −3.45 to 4.54) at 12 weeks, not significant (Kopp 2026).

Speculative 🟨

Endothelial function

Vessel-lining function improved in two independent trials: flow-mediated dilation (FMD, ultrasound-measured artery widening) in coronary patients (Enseleit 2012) and forearm blood flow in young men (Nishioka 2007). Neither endpoint is a validated treatment target.

Systemic inflammation markers ⚠️ Conflicted

A meta-analysis of five trials found lower CRP (C-reactive protein, a blood marker of inflammation) (Nikpayam 2018); a Zurich crossover trial found no change in inflammation markers (Enseleit 2012). Net reading: an inconsistent unvalidated signal.

Benefit-Modifying Factors

  • Genetic polymorphisms: No gene variant has been studied for Pycnogenol response; gut bacteria that convert procyanidins to the active metabolite M1 vary between people, and conjugation of constituents varied widely between volunteers (Grimm 2006).
  • Baseline biomarkers: Effects on glucose, blood pressure and vessel function appear in people with disease or dysfunction at baseline; in a healthy population, 200 mg/day did not change antioxidant status (Silliman 2003).
  • Sex: No sex-specific difference in response is documented; trials of menopause and melasma enrolled women only and erectile trials enrolled men only, so those findings apply to one sex.
  • Pre-existing conditions: Glucose reductions were seen in type 2 diabetes (Liu 2004); symptom benefits concern venous insufficiency, osteoarthritis or asthma. Healthy adults without these conditions have little measured benefit.
  • Age: The cognitive trial enrolled adults aged 60–85 and was tolerated (Ryan 2008); older adults are also more likely to have the venous, joint and metabolic conditions where benefits were reported.

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk reaches High: adverse-event data come from small, short trials not designed to detect harm, and no adverse event has been shown in excess of placebo by more than one independent group.

Medium 🟥 🟥

No risk reaches Medium: placebo-controlled trials report only mild, transient adverse events without a significant difference from placebo, and no controlled study shows an excess of any specific event.

Low 🟥

Mild gastrointestinal upset, dizziness and headache ⚠️ Conflicted

Mild stomach discomfort, dizziness, nausea and headache are the reported effects (Drugs.com monograph). In a placebo-controlled hypertension trial, these mild, transient effects occurred in both groups without a significant difference (Liu 2004). Net reading: mild, transient effects without a shown excess over placebo.

Magnitude: No significant between-group difference in mild gastrointestinal effects, vertigo, headache and nausea among 58 hypertensive patients; the trial reports no event rates for either group (Liu 2004).

Rhabdomyolysis with excess intake

A man taking pine bark extract above label doses developed severe rhabdomyolysis (muscle breakdown) after light lifting and was hospitalized for six days (Kermanshah 2025). A later correction relabeled the product generic pine bark extract rather than Pycnogenol (Kermanshah 2025). This single case shows possible, not proven, causation.

Magnitude: Creatine kinase (a muscle-damage marker) reached 154,000 U/L and fell to 7,874 U/L by day six with intravenous fluids; single case report, no control group (Kermanshah 2025).

Speculative 🟨

Bleeding when combined with drugs that slow blood clotting

Pycnogenol inhibits platelet aggregation without prolonging bleeding time on its own (Pütter 1999). Combined use with anticoagulants or antiplatelet drugs (medications that slow blood clotting) is unstudied; the concern is mechanistic only.

Low blood glucose with glucose-lowering drugs

Glucose fell further when Pycnogenol was added to diabetes drugs (Liu 2004), but no hypoglycemia (abnormally low blood glucose) was reported. The concern is mechanistic, from additive glucose lowering.

Immune stimulation

In cell studies intact Pycnogenol activated toll-like receptors (immune sensors of microbial signals), though gut-digested fractions were anti-inflammatory (Verlaet 2019). The autoimmune concern is mechanistic only.

Unknown safety in pregnancy and lactation

Safety data for pregnancy and breastfeeding are lacking; one small third-trimester trial used 30 mg/day (Kohama 2006; Drugs.com monograph). The basis for caution is the absence of data, not observed harm.

Forgone benefit when replacing proven therapy

Pycnogenol is promoted as an aspirin substitute, but no trial has measured heart attacks, strokes or clots in high-risk people. The concern is inferred from this gap, not from observed harm.

Risk-Modifying Factors

  • Genetic polymorphisms: No pharmacogenetic variant is known to change Pycnogenol’s safety; cytochrome P450 handling has not been studied in humans, and conjugation varies widely between individuals (Grimm 2006).
  • Baseline biomarkers: People with low baseline platelet counts or prolonged clotting times, low-normal fasting glucose on glucose-lowering drugs, or low blood pressure on blood pressure medication carry the most theoretical risk from additive effects.
  • Sex: No sex difference in adverse events is documented. Women who are or may become pregnant face the unresolved pregnancy question (Drugs.com monograph).
  • Pre-existing conditions: Bleeding disorders, autoimmune disease, organ transplantation and diabetes or hypertension treated with drugs raise theoretical risk through platelet, immune and additive drug effects.
  • Age: Older adults more often take anticoagulants, antiplatelets and several blood pressure or diabetes drugs, increasing the chance of additive effects; the trial in adults aged 60–85 reported no safety problem (Ryan 2008).

Key Interactions & Contraindications

Documented interactions:

  • Calcium channel blockers (blood pressure drugs that relax artery walls, such as nifedipine): In hypertensive patients, 100 mg/day allowed a lower nifedipine dose, an additive blood pressure-lowering effect (Liu 2004). Consequence: lower blood pressure; mitigation: home blood pressure checks when starting.
  • ACE inhibitors (angiotensin-converting enzyme inhibitors, blood pressure drugs such as enalapril or lisinopril): In type 2 diabetes with hypertension, 125 mg/day let 58% of patients halve their ACE inhibitor dose (Zibadi 2008). Consequence: additive lowering; mitigation: monitor blood pressure.
  • Oral glucose-lowering drugs (metformin; sulfonylureas, insulin-release stimulators such as glimepiride): Added to standard treatment, Pycnogenol lowered glucose further (Liu 2004). Consequence: potential hypoglycemia; mitigation: check fasting glucose during the first weeks.
  • SSRIs (selective serotonin reuptake inhibitors, antidepressants such as escitalopram): In an open trial, 50 mg/day with escitalopram eased sexual side effects but raised heart rate (Smetanka 2019). Consequence: higher resting heart rate; mitigation: monitor pulse.
  • L-arginine (an amino acid that feeds nitric oxide production): In a placebo-controlled trial in men with erectile dysfunction, 60 mg/day Pycnogenol with L-arginine and aspartic acid lowered blood pressure (Aoki 2012). Consequence: additive blood pressure lowering; mitigation: home blood pressure checks.

Theoretical interactions (inferred from mechanism, not studied in humans):

  • Anticoagulants and antiplatelet drugs (warfarin, apixaban, clopidogrel, aspirin): Inferred from platelet aggregation inhibition. Consequence: increased bleeding risk; mitigation: check INR (international normalized ratio, a clotting-time test) within 1–2 weeks on warfarin and watch for bruising.
  • Over-the-counter NSAIDs (nonsteroidal anti-inflammatory drugs such as ibuprofen, naproxen): Inferred from shared COX inhibition and platelet effects. Consequence: additive bleeding tendency and stomach irritation; mitigation: avoid regular combined high-dose use.
  • Immunosuppressants (drugs that dampen the immune system, such as cyclosporine, tacrolimus, azathioprine): Inferred from immune receptor activation in cell studies. Consequence: possibly reduced immunosuppression; mitigation: avoid unless the prescribing physician agrees.
  • Antiplatelet supplements (fish oil omega-3 fatty acids, ginkgo, garlic, high-dose vitamin E): Inferred from additive platelet inhibition. Consequence: increased bleeding tendency; mitigation: avoid stacking several before procedures.
  • Glucose-lowering supplements (berberine, cinnamon, alpha-lipoic acid): Inferred from additive glucose lowering. Consequence: low blood glucose in people on diabetes drugs; mitigation: monitor glucose.
  • Blood pressure-lowering supplements (L-citrulline, beetroot nitrate): Inferred from additive nitric oxide-mediated vasodilation. Consequence: lightheadedness or low blood pressure; mitigation: home blood pressure checks.
  • Surgery and invasive procedures: Inferred from platelet inhibition. Consequence: increased bleeding; mitigation: stop about 2 weeks before elective surgery.

Populations who should avoid Pycnogenol:

  • Pregnancy, especially the first trimester: A precaution in the American Botanical Council monograph, whose 2010 edition the maker paid for (NutraIngredients report), reported in a review (Simpson 2019); safety data are lacking (Drugs.com monograph); inferred from unstudied placental transfer of constituents, not from observed harm.
  • Breastfeeding: No human data (Drugs.com monograph); inferred from the unstudied transfer of the extract’s constituents and metabolites into breast milk, not from observed harm.
  • Children under 6 years: A precaution in the same American Botanical Council monograph, whose 2010 edition the maker paid for, reported in a review (Simpson 2019); inferred from the unstudied absorption and conjugation of the extract’s constituents in young children; no human data on harm.
  • Bleeding disorders (hemophilia or von Willebrand disease, inherited clotting-protein deficiencies): Inferred from platelet aggregation inhibition; no human data.
  • Organ transplant recipients on immunosuppressants: Inferred from immune receptor activation in cell studies; no human data.

Risk Mitigation Strategies

Doses and timings below follow common practice unless cited.

  • Take with meals: Gastrointestinal discomfort is the most common complaint; the American Botanical Council monograph, whose 2010 edition the maker paid for, advises taking it with food (reported in a review, Simpson 2019); this mitigates stomach upset and nausea.
  • Split doses: Dividing the daily amount into two or three portions (e.g., 50 mg three times daily) mitigates stomach upset and dizziness from a single larger dose.
  • Home blood pressure checks: For those on antihypertensives (blood pressure-lowering drugs), measuring blood pressure daily for the first 2 weeks prevents unnoticed additive lowering; dizziness or unusually low readings warrant medical review.
  • Glucose checks on diabetes drugs: Checking fasting glucose several times weekly for the first 4 weeks mitigates additive hypoglycemia; low readings or hypoglycemia symptoms warrant dose review with the prescriber.
  • INR check on warfarin: An INR test 1–2 weeks after starting mitigates bleeding risk from combined platelet and anticoagulant effects.
  • Pre-surgery pause: Stopping about 2 weeks before elective surgery or dental extraction mitigates procedural bleeding risk.
  • Branded, standardized product: Choosing products labeled as Pycnogenol meeting the USP (United States Pharmacopeia) monograph mitigates the risk of receiving a different extract without trial support.
  • Reassessment at 3 months: Stopping if target symptoms or markers have not changed by 3 months prevents prolonged use without benefit and avoids replacing proven therapies.

Therapeutic Protocol

Parameters other than doses without a citation (timing, splitting, titration, cycling) reflect common practice.

  • Standard dose: 150 mg/day in three divided doses is the most common trial regimen, within a studied range of 60–300 mg/day (Drugs.com monograph).
  • Practitioner dose: Chris Kresser suggests about 100 mg/day to reduce platelet aggregation (Kresser RHR podcast).
  • Popularizing source: The extract and most dosing data come from Horphag Research and its adviser Peter Rohdewald (his review, Rohdewald 2019); Life Extension, which sells Pycnogenol products, promotes it for longevity.
  • Low-dose approach: 60 mg/day (30 mg twice daily) was used for menopausal symptoms (Kohama 2013) and 50 mg/day with antidepressants (Smetanka 2019).
  • Higher-dose approach: 300 mg/day (100 mg three times daily) was used for venous insufficiency (Arcangeli 2000); 200 mg/day for menopause (Yang 2007) and vessel function (Enseleit 2012).
  • Dose-response: In type 2 diabetes, glucose lowering increased with dose from 50 to 200 mg/day (Liu 2004).
  • Time of day: No time-of-day effect has been studied; taking doses with meals, morning and evening, is the common pattern for tolerance.
  • Half-life: No single half-life applies to a multi-compound extract; constituents remain detectable for at least 14 hours after one dose, with the colonic metabolite M1 appearing later (Grimm 2006).
  • Single versus split dosing: Both are used; PYCNOVID gave 50 mg four times daily (Radtke 2024). Splitting with meals favors tolerance and steadier levels.
  • Genetic polymorphisms: No variant (e.g., APOE4, a gene variant raising Alzheimer risk; COMT, an enzyme that breaks down catecholamines) has been studied for Pycnogenol dosing.
  • Sex: No sex-specific dosing exists; women in menopause trials used 60–200 mg/day (Kohama 2013, Yang 2007).
  • Age: Adults aged 60–85 tolerated 150 mg/day for 3 months (Ryan 2008); with multiple medications, starting at the 50 mg/day used alongside antidepressants (Smetanka 2019) eases interaction monitoring.
  • Baseline biomarkers: Elevated fasting glucose, HbA1c or blood pressure define the groups in which trials found changes; normal baselines leave little room for measurable change.
  • Pre-existing conditions: Diabetes or hypertension on medication call for monitoring because trials reduced medication needs (Zibadi 2008); osteoarthritis trials used 100–150 mg/day (Belcaro 2008, Cisár 2008).

Discontinuation & Cycling

  • Duration: Trials lasted 2 weeks to 6 months; no data support or exclude lifelong use, so it is usually taken as an open-ended course and reassessed against its target symptoms.
  • Withdrawal effects: No withdrawal syndrome is reported; in children with ADHD, symptoms returned one month after stopping (Trebatická 2006), while reduced pain medication use for menstrual pain persisted after stopping (Suzuki 2008).
  • Tapering: No taper is needed for the extract itself; blood pressure or diabetes drug doses lowered during use may need readjustment after stopping.
  • Cycling: Cycling has not been studied and no loss of effect over 6 months has been reported, so continuous use is the common pattern.
  • Pre-procedure pause: A pause of about 2 weeks before elective surgery is common practice because of platelet effects.

Sourcing and Quality

  • Trademark versus generic: Pycnogenol is Horphag Research’s trademarked extract; other pine bark extracts (Flavangenol, Oligopin, Pinus radiata extracts such as Enzogenol) differ in composition, and their trials, such as Drieling 2010, do not transfer.
  • Standardization: Quality products state conformity with the USP monograph “Maritime Pine Extract” and 65–75% procyanidins (a review, Bayer 2024).
  • Mislabeling history: Grape seed extract was once sold as “pycnogenol” (Drugs.com monograph); the registered trademark symbol and named supplier on the label distinguish licensed products.
  • Third-party testing: ConsumerLab has not tested Pycnogenol products; a certificate of analysis or a USP or NSF certification seal supports identity and purity.
  • Reputable brands: Licensed Pycnogenol is sold by Life Extension, NOW Foods, Pure Encapsulations, Natrol and others; the raw material comes from one supplier, so brand differences concern dose, inactive ingredients and price.
  • Combination products: Products pairing Pycnogenol with L-arginine (e.g., Prelox) have their own trials, pooled in a meta-analysis (Tian 2023); results do not apply to Pycnogenol alone.

Practical Considerations

  • Time to effect: Venous symptoms improved within 4–8 weeks (Arcangeli 2000), menopausal symptoms within 4–12 weeks (Kohama 2013), and joint symptoms over 3 months; allergy benefit required starting at least 5 weeks before pollen season (Wilson 2010).
  • Common pitfalls: Buying generic pine bark or grape seed extract, expecting antioxidant benefits in healthy people, stopping prescribed drugs, and treating manufacturer-funded results as independently confirmed.
  • Regulatory status: In the US it is sold as a dietary supplement; the FDA (Food and Drug Administration) does not approve supplements for safety or effectiveness before sale (FDA dietary supplement Q&A).
  • Cost and access: It is widely available without prescription and is not exceptionally expensive; cost scales with dose, with 200 mg/day costing roughly twice a 100 mg/day regimen.

Interaction with Foundational Habits

  • Sleep: Indirect, potentially supportive: in perimenopausal women, 60 mg/day improved insomnia and sleep problems more than placebo (Kohama 2013). No sleep disruption has been reported, and no data exist outside menopause.
  • Nutrition: Indirect: taking it with food reduces stomach upset. Its procyanidins overlap with those in cocoa, tea and apples, and gut bacteria produce the active metabolite M1, so a fiber-rich diet may matter; no nutrient depletion is known.
  • Exercise: None known: no trial shows blunted training adaptations, a concern raised for high-dose vitamins C and E but untested for Pycnogenol. Timing relative to workouts has not been studied; vasodilation offers a plausible but unproven performance mechanism.
  • Stress management: Indirect and unconfirmed in adults: no cortisol data exist; in children with ADHD, urinary dopamine fell and the stress hormones adrenaline and noradrenaline trended down during supplementation (Dvořáková 2007).

Monitoring Protocol & Defining Success

Before starting, a baseline panel establishes reference points for the markers Pycnogenol is expected to change and for safety checks. This includes fasting glucose and HbA1c, a lipid panel, high-sensitivity CRP, and seated home blood pressure averaged over a week. For warfarin users, a current INR is part of the baseline. A written baseline of target symptoms, such as leg heaviness, joint pain or hot flashes, makes later comparison possible.

Ongoing monitoring follows a cadence of a check at 2–4 weeks for blood pressure, glucose and INR in people on interacting drugs, then laboratory markers at 3 months, then every 6–12 months while use continues. Success is a measurable change in the target symptom or marker by 3 months; without one, stopping is the default reassessment.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Fasting glucose 70–99 mg/dL (standard reference range) Expected to change; safety check on diabetes drugs Fast 8–12 hours; pair with HbA1c; reductions were modest in a meta-analysis (Malekahmadi 2019)
HbA1c 4.0–5.6% (standard reference range) Expected to change in type 2 diabetes Reflects about 3 months, so recheck no sooner than 3 months; no fasting needed
Blood pressure <130/80 mm Hg (ACC/AHA guideline target) Safety check on antihypertensives; possible small change ACC/AHA: American College of Cardiology/American Heart Association; source: Whelton 2018; the authoring societies represent clinicians whose patient numbers grow with lower treatment thresholds, a potential financial interest; no laboratory reference range exists for blood pressure; use morning home readings after 5 minutes seated
LDL cholesterol <100 mg/dL (standard reference range) Expected to change slightly Fasting optional; pair with HDL and triglycerides; effects inconsistent; one meta-analysis found no LDL change (Hadi 2019)
hs-CRP No established target; track change from the individual’s own baseline Expected to change hs-CRP: high-sensitivity C-reactive protein; avoid testing during acute illness; pooled reduction in Nikpayam 2018
INR (warfarin users only) No established target for this purpose; track change from the individual’s own stable values Safety check Recheck 1–2 weeks after starting; the prescriber’s warfarin target range applies

Qualitative markers:

  • Leg heaviness, swelling and evening ankle puffiness
  • Joint pain, stiffness and walking distance
  • Hot flashes and sleep quality in perimenopause
  • Stomach comfort, dizziness and headache after doses
  • Easy bruising, gum bleeding or nosebleeds

Emerging Research

  • Gulf War illness dose-ranging trial: For Gulf War illness (chronic fatigue, pain and cognitive symptoms in 1991 Gulf War veterans), a Birmingham, Alabama, placebo-controlled trial tests 100–600 mg/day in 20 veterans, measuring self-reported physical and mental function (NCT07266571); not yet recruiting. A positive result would support fatigue-type benefits; a null result would weaken them.
  • Postmenopausal inflammation trial: A Taipei Medical University trial of 100 mg/day for 30 days in 46 postmenopausal women, measuring quality of life plus antioxidant and inflammatory gene expression (NCT07855198); not yet recruiting. A positive result would add mechanistic support; a null result would leave the inflammation item Speculative.
  • PYCNOVID peer-reviewed report: The Zurich post-COVID trial (NCT05890534) completed in January 2025 with no results posted on the registry; a peer-reviewed secondary analysis reports no difference from placebo in self-rated health (Kopp 2026).
  • Fish oil plus pine bark extract in cognitive decline: A Taipei trial of Oligopin, a different pine bark extract, with fish oil in 60 adults (NCT05573269) passed its July 2023 completion date; status unknown, no results posted. Results would be indirect for Pycnogenol.
  • University-led inflammation trials: A Würzburg university trial found lower salivary MMP-8 (a collagen-degrading enzyme) and serum IL-6 (interleukin-6, an inflammatory signal) during gum treatment (Bayer 2025); replication with clinical endpoints could strengthen the inflammation case.
  • Independent replication of core benefits: The venous, joint and glucose findings rest on small manufacturer-linked trials, per the Cochrane review (Robertson 2020); larger independent trials could confirm them or weaken them, as PYCNOVID and a double-blind-only meta-analysis (Fogacci 2020) did for post-COVID symptoms and blood pressure.

Conclusion

Pycnogenol is a branded extract of French maritime pine bark that acts mainly on the inner lining of blood vessels, on inflammation and on the clumping of blood clotting cells. For health-focused adults, the most consistent human findings are relief of leg heaviness and swelling from weak leg veins, of menopausal symptoms and of asthma symptoms, better vision in diabetic eye damage, with further support for slightly lower cholesterol that builds up in arteries, knee joint pain, blood sugar control in type 2 diabetes, erectile function and memory in older adults. Effects on blood pressure and body weight are small and inconsistent, and the most tightly controlled trials of blood pressure and of lingering symptoms after a coronavirus infection found none.

The extract is well tolerated in trials, with mild stomach upset, dizziness and headache as the usual complaints. The main practical concerns are added effects with anticlotting drugs, blood pressure drugs and diabetes drugs, and the lack of safety data in pregnancy.

The evidence base is large in number but weak in quality. Most trials are small and short, and most were paid for by the maker, often with its long-time adviser as co-author or run by one Italian group. Independent reviewers rated nearly all of it as very low certainty, and the few larger independent trials gave mixed answers. For this audience, Pycnogenol is a low-risk option with plausible benefits for specific circulation, joint and metabolic complaints, resting on evidence that leans heavily on its maker.

Top - Benefits - Risks - Protocol